Table 2 Demographic data of the selected home-isolating COVID-19 patients
Characteristic | N (%) (Total N = 197) |
|---|---|
Gender | |
Male | 101 (51.26) |
Age (years), median (IQR) | 45 (33–55) |
Underlying disease | 70 (35.53) |
Hypertension | 31 (44.29) |
Dyslipidemia | 20 (28.57) |
Diabetes mellitus | 16 (22.86) |
Liver disease | 8 (11.43) |
Obesity | 7 (10.00) |
Neurological disease | 3 (4.29) |
Cancer | 2 (2.86) |
Others | 25 (35.71) |
Concomitant of medication for chronic illness | 55 (27.92) |
Favipiravir dosage | |
Standard dose | 185 (93.91) |
High dose | 12 (6.09) |
Post COVID-19 vaccination | 121 (61.42) |
1 dose | 72 (59.50) |
2 dose | 48 (39.67) |
3 dose | 1 (0.83) |
Concomitant of OTC, herb, and dietary supplement for COVID-19 | 91 (46.19) |
Vitamin C | 34 (37.36) |
Andrographis paniculata extract capsule or tablets | 29 (31.87) |
Boesenbergia rotunda extract (total n = 25) | 25 (27.47) |
Capsule or tablet | 11 (44.00) |
Herbal drink | 10 (40.00) |
Inhalation | 3 (12.00) |
Crude herb | 1 (4.00) |
Ginger (total n = 22) | 22 (24.18) |
Herbal drink | 21 (95.45) |
Crude herb | 1 (4.55) |
Mixed herbs (total n = 15) | 15 (16.48) |
Capsule or tablet | 2 (13.33) |
Herbal drink | 4 (26.67) |
Inhalation | 9 (60.00) |
Others | 29 (31.87) |